GoBalto adds ChinaBio's list of contract research organisations to website

US-based goBalto, a website that enables drug development companies to find partners, share knowledge and discover opportunities, has put ChinaBio's proprietary list of more than 260 China-based contract research organisations (CROs) and contract manufacturing organisations (CMOs) up on the site.

US-based goBalto, a website that enables drug development companies to find partners, share knowledge and discover opportunities, has put ChinaBio's proprietary list of more than 260 China-based contract research organisations (CROs) and contract manufacturing organisations (CMOs) up on the site.

ChinaBio tracks the biotech and life science industries in China. Its list of CROs and CMOs is divided into two categories: sourced by ChinaBio and reviewed by ChinaBio. The first category indicates that ChinaBio has identified these organisations as actively operating in China and that information on them is maintained in its database. Firms in the second category have been visited by ChinaBio, which met senior management and reviewed their specific capabilities. More than 40 of the CROs and CMOs listed on goBalto have been reviewed to date.

"Interfacing ChinaBio's list to our platform enables users more quickly and easily to evaluate the leading CROs and CMOs in the region and become informed about the exciting, high-growth China market," said Jae Chung, founder and ceo of goBalto.

According to PricewaterhouseCoopers, the CRO market in China was worth US$186m (123m) in 2007, up 38% from 2006. Driven mainly by outsourcing from international firms, it is projected to grow at an estimated 33.5% annually, bringing the market to nearly US$791m by 2012. By comparison, the global CRO market is growing at 12.6% a year.